Johns Hopkins University

Trending Articles

  1. Counteracting counterfeits in the pharmaceutical supply chain Sreedhar Patnala, General Manager at Systech, discusses the comprehensive benefits of embracing traceability
  2. Catalent Boston adds to oral spray drying capacity to support late-stage clinical trials and commercialisation Catalent, the leading provider of oral drug development solutions, bioavailability enhancing technologies and flexible manufacturing, has completed a series of upgrades to its...
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  4. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human...
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Industrial data mastery: navigating the 2025 landscape As industrial manufacturers contend with the ever-increasing volume and variety of operational data, the year ahead promises both complexity and opportunity

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

Related Content

Ingredients

Study shows plant extracts outperform antibiotics against Lyme disease

A preclinical study in test tubes has shown that selected plant-based herbal medicines work better than doxycycline and cefuroxime
Research & Development

Bayer HealthCare and Johns Hopkins University to collaborate on new ophthalmic therapies

The partners will work jointly on the discovery and development of innovative drugs for the treatment of serious back-of-the-eye diseases
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Building the framework for precision medicine

As science unravels the genome, clinicians have the potential of linking genes to disease. Providing targeted, effective therapies still requires major efforts in data gathering, new clinical infrastructure and new regulation - but will it also mean smaller profits? Susan Birks reports
Subscribe now